Rejenevie™ Therapeutics Announces Start of Phase II Immune Restoration Treatment Clinical Trial
Promising anti-aging stem cell therapy AR-100 shows potential in the treatment of age-related diseases
HOUSTON, May 29, 2019 — Rejenevie™ Therapeutics announced the commencement of the company’s Phase II clinical trial to study the safety and effectiveness of its proprietary AR-100 immune restoration therapy to boost the function of the aging immune system. The clinical-stage biotechnology company develops first-in-world stem cell restoration treatments targeting age-related diseases.